Avacta Group plc: Faridoxorubicin Treatment Results in Near Doubling of Progression-Free Survival and Clinically Meaningful Tumor Shrinkage in Most Patients with Salivary Gland Cancers
Durability of faridoxorubicin (AVA6000) activity results from the continued release of doxorubicin by fibroblast activation protein (FAP) demonstrated beyond 10 cycles of therapy
Covered in this story
Call it yourself
No calls on $AVA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Avista Corp →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.